WIN symposium brings worldwide pharma, biotech and academics together
Posted: Wednesday, April 13, 2011
The 3rd WIN Symposium, endorsed by E.O.R.T.C., brings worldwide pharma, biotech, and academics together to address the rapidly advancing field of personalized cancer medicine.
Worldwide Innovative Networking (WIN) Consortium announces the scientific program of its 3rd annual symposium to be held from 6th to 8th July 2011 at the Palais des Congrès in Paris, France (http://www.winconsortium.org/symposium.html).
The WIN Symposium will inaugurate an unprecedented format, where pharma, biotech, academia and patient organizations will be giving their views on how to address the challenges of efficacy of cancer diagnostics and therapeutics in the era of personalized healthcare, to the benefit of the patient.
‘’We aim to create a forum for open discussion in which the expertise and input from all stakeholders in targeted cancer drug development are crucial’’ said Dr. John Mendelsohn, Chairman of the WIN Consortium and President of the University of Texas MD Anderson Cancer Center.
Speakers from Pharma and Biotech
Mike Burgess, Robert Wasserman, Peter-Ulrich Rohr (Roche), Gary Gilliland (Merck and Co), Nick Botwood (Astra Zeneca), Shannon Morris (GlaxoSmithKline), Samit Hirwat (Novartis), Antonella Isacchi (Nerviano Medical Sciences), Paul Billings and Martin Naley (Life Technologies), Leo Bonilla (Agilent Technologies) and Ian Wilson (GE Healthcare).
Speakers from Academia and Patient Organizations
John Mendelsohn, Razelle Kurzrock and Donald Berry (UT-MDAnderson Cancer Center), Samir Hanash (Fred Hutchinson Cancer Center), Leroy Hood (Institut for Systems Biology Seattle), David Sidransky (Johns Hopkins University), Stephen Friend (Sage Bionetworks), Keneth Anderson (Dana Farber Cancer Institute), Alexander Eggermont, Jean-Charles Soria (Institut Gustave Roussy), Janelle Hail (National Breast Cancer Foundation), Julio E. Celis (Danish Cancer Society), Denis Lacombe
(EORTC), Robert Kerbel (Sunnybrook Health Sciences Center), Dominique Stoppa-Lyonnet (Institut Curie) and many others.
• Evidence for efficacy of targeted therapeutics
• Improving the efficacy of biomarker-driven clinical trials
• Combinations of targeted drugs
• Discovering and validating new targets and predictive biomarkers
• Advances in technology, bioinformatics and systems biology
• Strategic alliances to fight cancer
‘’A synthesis of the symposium, will be presented by Dr. Richard L. Schilsky, Chairman of the WIN Scientific Advisory Board, aiming to present concrete perspectives to improve clinical outcomes and the quality of life for cancer patients worldwide” says Vladimir Lazar, WIN Chief Operating Officer
Vladimir Lazar, Chief Operating Officer
Catherine Bresson, Director of Operational Team